SEC Form F-1 filed by MEDIROM Healthcare Technologies Inc.
Unavailable
Unavailable
TOKYO, June 25, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) ("Medirom" or the "Company"), a holistic healthcare company based in Japan, announced it filed its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC"), including consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), on June 18, 2024. Kouji Eguchi, Chief Executive Officer of the Company, stated, "I am very pleased to announce that during a period of significant investment and development in our healthcare technology systems and products in FY 2023 and FY 2022, as wel
NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the "Company"), today announced its preliminary unaudited financial results for the fiscal year ended December 31, 2021, prepared in accordance with U.S. GAAP. Due to additional time required to complete its year-end reporting process, the Company determined that it was unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2021, within the prescribed time period without unreasonable effort and expense. The Company filed a Notification of Late Filing on Form 12b-25 with the U.S. Securities and Exchange Commission o
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM, "MEDIROM"), a leading holistic health services provider in Japan, today announced MEDIROM's interim financial results for the six month ended June 30, 2021. FY 2021 Interim Financial Highlights Total revenue for the first half of the year increased by 57.0% to JPY2,127 million (US$19.1 million) from JPY1,356 million in a year ago period, due to the recovery from the COVID-19 negative impact in 2020.Cost of revenues increased by 39.4% to JPY1,768 million (US$15.9 million) from JPY1,269 million in a year ago period, as a result of the reopening of the salons and salon acquisitions.SG&A increase
6-K - Medirom Healthcare Technologies Inc. (0001819704) (Filer)
F-1 - Medirom Healthcare Technologies Inc. (0001819704) (Filer)
6-K - Medirom Healthcare Technologies Inc. (0001819704) (Filer)
SC 13D - Medirom Healthcare Technologies Inc. (0001819704) (Subject)
SC 13D - Medirom Healthcare Technologies Inc. (0001819704) (Subject)
TOKYO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. ((Headquarters: Minato-ku, Tokyo, CEO: Koji Eguchi, listed on Nasdaq, NASDAQ:MRM, hereinafter "MEDIROM")) announces that its subsidiary MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku, Tokyo; CEO: Yoshio Uekusa; hereinafter "MOTHER Labs"), has formed a capital and business alliance with NFES Technologies Inc. (Headquarters: Matsue City, Shimane Prefecture; CEO: Keita Adachi; hereinafter "NFES Group"), a subsidiary of NFES Inc. (Headquarters: Matsue City, Shimane Prefecture; CEO: Keita Adachi). As part of this alliance, NFES Group has agreed to participate as the lead investor in MOTHER Labs' Series A financi
TOKYO, July 22, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. ("we", "our", "us" or "the Company") hereby announces that its subsidiary MEDIROM Rehab Solutions Inc. entered into an agreement to purchase a rehabilitation business from Y's, Inc., a Japanese corporation, as of July 10, 2024. Y`s, Inc. operates 10 rehabilitation facilities around Tokyo for survivors of cerebral infarction, a type of stroke, and the company does business with major private, public and university hospitals in Japan. Y's, Inc. started its Cerebral Infarction Rehabilitation Center business with an awareness that people suffering from the aftereffects of cerebral infarction are not receiving adeq
NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. ("we", "our", "us" or "the Company") hereby announces that the Company plans to acquire a majority of Japan Gene Medicine Corporation (the "Target Company"). On June 30, 2024, the Company entered into a share transfer agreement (the "Share Transfer Agreement") to acquire 70.0% of the shares of the Target Company from an individual shareholder. The Company has also entered into a legally binding memorandum of understanding (the "Additional Transfer Memorandum of Understanding"), effective as of June 30, 2024, to obtain an option to acquire the remaining 30.0% of the Target Company's shares from the seller. The
MEDIROM Healthcare Technologies Inc. ("we", "our", "us" or "the Company") hereby announces that its subsidiary MEDIROM Rehab Solutions Inc. entered into an agreement to purchase a rehabilitation business from Y's, Inc., a Japanese corporation, as of July 10, 2024. Y`s, Inc. operates 10 rehabilitation facilities around Tokyo for survivors of cerebral infarction, a type of stroke, and the company does business with major private, public and university hospitals in Japan. Y's, Inc. started its Cerebral Infarction Rehabilitation Center business with an awareness that people suffering from the aftereffects of cerebral infarction are not receiving adequate rehabilitation. The goal is to create a s
NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan ("MEDIROM", the "Company"), today announced it will participate in a "NASDAQ JAPAN IR EVENT" to be held at Nasdaq MarketSite in Times Square on June 20, 2024. Five companies are currently expected to join this event (including one private company), and we will share information about the attractive nature of the Japanese market with a global audience. PurposeIn December 2020, the Company became the first Japanese company in 21 years to list on Nasdaq. Today, the number of Japanese companies listed on Nasdaq has increased to eight. While more and mor